Slide 1: Investors Update – Q2FY11
Investors Update – Q2FY11 • Net sales up 28% at Rs 365 crores against Rs. 286 crores in corresponding quarter last year • Domestic Branded formulations up 27% at Rs. 207 crores against Rs. 163 crores in corresponding quarter last year • Total API sales up 33% at Rs. 100 crores against Rs. 75 crores
Slide 2: Management Discussion – Q2FY11
Management Discussion – Q2FY11 Alembic Limited, the pharmaceutical major, today reported a 28% increase in revenues to Rs 365.42 crores for the quarter ended 30th September 2010, compared to Rs 285.99 crores in the corresponding quarter last year. The Company posted an impressive 72% growth in net p
Slide 3: ORG IMS Aug '10 MAT Growth by segment and brand ranks
(ORG IMS – Aug ‘10 MAT Growth %) Segment Alembic Industry Cough and Cold 28 24 Gastro 24 20 Cardio 26 21 Diabeto 36 31 Opthal 451 21 The ORG ranks of some of our top brands have improved and are as follows: Brands Rank Aug 10 Azithral 17 Althrocin 20 Roxid 66 Wikoryl 120 Zeet 242 Alembic’s key molec
Slide 4: International generics grew by 10%
International generics grew by 10% to Rs. 39.79 crores from Rs. 36.14 Crores over corresponding quarter last year Alembic’s strategy is to partner with International Generic companies and leverage on their marketing and sales capabilities. Regulatory filings till date total 31 ANDAs with 9 approvals
Slide 5: Domestic API sales grew 127%
Domestic API sales grew 127% at Rs. 54.65 crores against Rs. 24.12 crores of PY. Export API recorded sales of Rs. 45.26 crores against Rs. 50.73 crores. 39 Drug Master files (DMF) have been filed till date. Export Sales Total Revenue 40000 12000 Domestic Business 35000 10000 Regulatory Sales Export
Slide 6: Net interest costs and Scheme of Rearrangement
Net Interest costs during the quarter were lower at Rs. 6.64 crores compared to Rs. 9.01 crores largely on account of reduction in borrowing costs. Scheme of Rearrangement: The Board of Directors of the Company in its meeting held on 29th June, 2010 has approved scheme of arrangement containing deme
Slide 7: Scheme of Arrangement approvals
volatility and uncertainty of Pen G business of Vadodara manufacturing facility. As per directions of The Hon’ble High Court of Gujarat separate meetings of Secured Creditors, Un-Secured Creditors, Shareholders and Fixed Deposit Holders was held on 16th September, 2010 for approval of the Scheme of
Slide 8: Financial and Operating Result - Q2FY11
Financial and Operating Result - Q2FY11 Particulars Q2FY11 Q2FY10 Gr % Income from Operations 36343 28490 28% Total Expenditure 31933 24996 28% - (Increase) / decrease in stock (1,602) (673) - Consumption of Raw Material 13632 9095 - Consumption of Traded Goods 4882 4507 31% - Employee cost 4607 385
Slide 9: Business Performance and Profit break-up for the quarter
Business Performance - Rs. Sales Lacs Particulars Formulations Bulk Total Gr Q2FY11 Q2FY10 % Q2FY11 Q2FY10 Gr % Q2FY11 Q2FY10 Gr % Domestic 20683 16255 27% 5465 2412 127% 26148 18667 40% International - Regulatory 3979 3614 10% 2217 3209 -31% 6196 6823 -9% International - ROW 1514 1007 50% 2309 1864
Slide 10: Break up of Alembic Pharma Limited / Alembic Limited
Break up of Alembic Pharma Limited / Alembic Limited Sales and Profit break up of both businesses depicted below are as per best estimate of management and have not been audited (Rs. in Lacs) Particulars Pharma Operations Baroda Operations (Proposed Alembic (Proposed Alembic Total Pharma Limited) Li
Slide 11: About Alembic Limited
About Alembic Limited Established in 1907, Alembic Ltd. is a leading pharmaceutical company in India. The company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in Macroli